(Q37473177)

20 August 2017

1 reference

title

Renal toxicity of targeted therapies (English)

1 reference

20 August 2017

0 references

0 references

3

Olivier Rixe

1 reference

20 August 2017

Ronan J Kelly

1

1 reference

20 August 2017

Bertrand Billemont

series ordinal

2

1 reference

20 August 2017

publication date

1 April 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

4

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

121-133

1 reference

Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms

20 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11523-009-0109-X

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11523-009-0109-X

Monoclonal antibody therapies for solid tumors

21 January 2018

1 reference

12 December 2020

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

12 December 2020

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

12 December 2020

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

1 reference

12 December 2020

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

1 reference

12 December 2020

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

12 December 2020

New challenges in kidney cancer therapy: sunitinib

1 reference

12 December 2020

A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial

1 reference

12 December 2020

Hypoxia-inducible factors in the kidney

1 reference

12 December 2020

Expression of hypoxia-inducible transcription factors in developing human and rat kidneys.

1 reference

12 December 2020

Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways.

1 reference

12 December 2020

Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer

1 reference

12 December 2020

1 reference

12 December 2020

Segment-specific c-ErbB2 expression in human autosomal recessive polycystic kidney disease

1 reference

12 December 2020

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

1 reference

12 December 2020

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

12 December 2020

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

1 reference

12 December 2020

Drug development of MET inhibitors: targeting oncogene addiction and expedience

1 reference

12 December 2020

Emerging therapeutic options for breast cancer chemotherapy during pregnancy

1 reference

12 December 2020

Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer

1 reference

12 December 2020

Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia

1 reference

12 December 2020

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101

1 reference

12 December 2020

Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib

1 reference

12 December 2020

Anticancer drug-induced kidney disorders

1 reference

12 December 2020

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

12 December 2020

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology

1 reference

12 December 2020

Notch inhibition reverses kidney failure

1 reference

12 December 2020

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

12 December 2020

Nephrotic syndrome after bevacizumab: case report and literature review

1 reference

12 December 2020

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

12 December 2020

Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach

1 reference

12 December 2020

Sorafenib in advanced hepatocellular carcinoma

1 reference

12 December 2020

A quantitative analysis of kinase inhibitor selectivity

1 reference

12 December 2020

Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma

1 reference

12 December 2020

Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

1 reference

12 December 2020

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

1 reference

12 December 2020

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron.

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Randomized trial of bevacizumab in advanced renal cell carcinoma

1 reference

12 December 2020

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

1 reference

12 December 2020

Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.

1 reference

12 December 2020

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

1 reference

12 December 2020

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure

1 reference

12 December 2020

Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy

1 reference

12 December 2020

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

12 December 2020

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

12 December 2020

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer

1 reference

12 December 2020

Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

1 reference

12 December 2020

Interstitial nephritis in a patient taking sorafenib

1 reference

12 December 2020

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

12 December 2020

Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

1 reference

12 December 2020

Hypertension as a predictive factor of Sunitinib activity

1 reference

12 December 2020

Roles for VEGF in the adult.

1 reference

12 December 2020

The Notch pathway in podocytes plays a role in the development of glomerular disease

1 reference

12 December 2020

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

12 December 2020

HER2-positive breast cancer: current treatment strategies

1 reference

12 December 2020

Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries.

1 reference

12 December 2020

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

12 December 2020

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases

1 reference

12 December 2020

Acute renal failure secondary to imatinib mesylate treatment in prostate cancer.

1 reference

12 December 2020

High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes

1 reference

12 December 2020

Notch signalling: a simple pathway becomes complex

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Hepatocyte growth factor: new arsenal in the fights against renal fibrosis?

1 reference

12 December 2020

Thrombotic microangiopathy and anti-VEGF agents

1 reference

12 December 2020

Activation of ERK or inhibition of JNK ameliorates H(2)O(2) cytotoxicity in mouse renal proximal tubule cells

1 reference

12 December 2020

Oxygen sensing by HIF hydroxylases

1 reference

12 December 2020

EGFR family: structure physiology signalling and therapeutic targets

1 reference

12 December 2020

Role of the VEGF--a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier

1 reference

12 December 2020

Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies

1 reference

12 December 2020

Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues

1 reference

12 December 2020

VEGF inhibition and renal thrombotic microangiopathy

1 reference

12 December 2020

Focal segmental glomerulosclerosis: recent advances

1 reference

12 December 2020

Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib

1 reference

12 December 2020

Imatinib mesilate for the treatment of gastrointestinal stromal tumour

1 reference

12 December 2020

A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer

1 reference

12 December 2020

Stretch-induced VEGF expression in the heart

1 reference

12 December 2020

Vascular endothelial growth factor localization in the adult.

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

CREB mediates ERK-induced survival of mouse renal tubular cells after oxidant stress.

1 reference

12 December 2020

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

12 December 2020

10.1007/S11523-009-0109-X

Identifiers

DOI

1 reference

20 August 2017

1 reference